A detailed history of Advisor Group Holdings, Inc. transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 10,200 shares of ATOS stock, worth $13,056. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,200
Previous 10,950 6.85%
Holding current value
$13,056
Previous $13,000 15.38%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.09 - $1.52 $817 - $1,140
-750 Reduced 6.85%
10,200 $15,000
Q2 2024

Aug 13, 2024

SELL
$1.03 - $2.1 $618 - $1,260
-600 Reduced 5.19%
10,950 $13,000
Q4 2023

Feb 12, 2024

SELL
$0.63 - $0.98 $1,384 - $2,153
-2,197 Reduced 15.98%
11,550 $10,000
Q3 2023

Nov 13, 2023

SELL
$0.74 - $1.35 $1,110 - $2,025
-1,500 Reduced 9.84%
13,747 $10,000
Q2 2023

Aug 10, 2023

SELL
$0.6 - $1.28 $138 - $294
-230 Reduced 1.49%
15,247 $19,000
Q1 2023

May 12, 2023

SELL
$0.59 - $0.91 $749 - $1,155
-1,270 Reduced 7.58%
15,477 $11,000
Q4 2022

Feb 10, 2023

SELL
$0.5 - $1.01 $1,525 - $3,080
-3,050 Reduced 15.41%
16,747 $8,000
Q1 2022

May 04, 2022

SELL
$1.11 - $1.74 $1,805 - $2,830
-1,627 Reduced 7.59%
19,797 $25,000
Q3 2021

Nov 05, 2021

BUY
$2.89 - $6.4 $4,285 - $9,491
1,483 Added 7.44%
21,424 $70,000
Q2 2021

Aug 02, 2021

SELL
$1.52 - $8.62 $5,920 - $33,574
-3,895 Reduced 16.34%
19,941 $127,000
Q1 2021

May 13, 2021

BUY
$0.92 - $4.33 $21,001 - $98,845
22,828 Added 2264.68%
23,836 $50,000
Q3 2020

Nov 12, 2020

BUY
$1.98 - $4.35 $1,995 - $4,384
1,008 New
1,008 $2,000

Others Institutions Holding ATOS

About ATOSSA THERAPEUTICS, INC.


  • Ticker ATOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,624,000
  • Market Cap $162M
  • Description
  • Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...
More about ATOS
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.